An international working group within the European LeukemiaNet gathered, aiming to determine the role of flow cytometry (FC) in myelodysplastic syndromes (MDS). It was agreed that FC has a substantial application in disease characterization, diagnosis and prognosis. FC may also be useful in predicting treatment responses and monitoring novel and standard therapeutic regimens. In this article the rationale is discussed that flow cytometry should be integrated as a part of diagnostic and prognostic scoring systems in MDS.

, , ,
doi.org/10.3109/10428194.2012.718341, hdl.handle.net/1765/68411
Leukemia and Lymphoma
Department of Immunology

van de Loosdrecht, A.A, Ireland, R, Kern, W, Della Porta, M.G, Alhan, C, Balleisen, J.S, … Westers, T.M. (2013). Rationale for the clinical application of flow cytometry in patients with myelodysplastic syndromes: Position paper of an International Consortium and the European LeukemiaNet Working Group. Leukemia and Lymphoma (Vol. 54, pp. 472–475). doi:10.3109/10428194.2012.718341